SVRA
NASDAQ · Biotechnology
Savara Inc
$5.51
+0.10 (+1.85%)
Open$5.43
Previous Close$5.41
Day High$5.53
Day Low$5.36
52W High$7.01
52W Low$2.43
Volume—
Avg Volume1.63M
Market Cap1.20B
P/E Ratio—
EPS$-0.56
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,042.3% upside
Current
$5.51
$5.51
Target
$62.94
$62.94
$52.50
$62.94 avg
$80.97
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 135.25M | 127.87M | 115.53M |
| Net Income | 19.67M | 13.91M | 14.59M |
| Profit Margin | 14.5% | 10.9% | 12.6% |
| EBITDA | 27.67M | 31.26M | 23.85M |
| Free Cash Flow | 12.49M | 17.00M | 15.12M |
| Rev Growth | +10.1% | -5.7% | +15.6% |
| Debt/Equity | 0.38 | 0.46 | 0.53 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |